Microbiome Firm Second Genome Completes $5M Series A Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Microbiome technology firm Second Genome today announced the closing of a Series A financing round that raised $5 million.

The round was co-led by new investors Advanced Technology Ventures and Morgenthaler Ventures, as well as existing investors Wavepoint Ventures, Seraph Group, and individual investors.

The company, which was founded in 2009 as PhyloTech, also said that Mike Carusi of ATV and Jason Lettmann of Morgenthaler have joined its board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.